Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Ciprofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid. The primary mechanism of action of ciprofloxacin is inhibition of bacterial DNA gyrase. It is a broad spectrum antibacterial drug to which most Gram-negative bacteria are highly susceptible in vitro and many Gram-positive bacteria are susceptible or moderately susceptible. Unlike most broad spectrum antibacterial drugs, ciprofloxacin is effective after oral or intravenous administration. Ciprofloxacin has been most extensively studied following oral administration. It attains concentrations in most tissues and body fluids which are at least equivalent to the minimum inhibitory concentration designated as the breakpoint for bacterial susceptibility in vitro. The results of clinical trials with orally and intravenously administered ciprofloxacin have confirmed the potential for its use in a wide range of infections, which was suggested by its in vitro antibacterial and pharmacokinetic profiles. It has proven an effective treatment for many types of systemic infections as well as for both acute and chronic infections of the urinary tract. Ciprofloxacin generally appeared to be at least as effective as alternative orally administered antibacterial drugs in the indications in which they were compared, and in some indications, to parenterally administered antibacterial therapy. However, further studies are needed to fully clarify the comparative efficacy of ciprofloxacin and standard antibacterial therapies. Bacterial resistance to ciprofloxacin develops infrequently, both in vitro and clinically, except in the setting of pseudomonal respiratory tract infections in cystic fibrosis patients. The drug is also well tolerated. Thus, as an orally active, broad spectrum and potent antibacterial drug, ciprofloxacin offers a valuable alternative to broad spectrum parenterally administered antibacterial drugs for use in a wide range of clinical infections, including difficult infections due to multiresistant pathogens.

[1]  P. Piot,et al.  In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae , 1984, Antimicrobial Agents and Chemotherapy.

[2]  Scully Be,et al.  Treatment of serious infections with intravenous ciprofloxacin. , 1987 .

[3]  T. Bergan,et al.  Crystalluria and ciprofloxacin, influence of urinary pH and hydration. , 1986, Chemotherapy.

[4]  D. Bouanchaud,et al.  Comparative efficacy of pefloxacin and six other antimicrobial agents on Staphylococcus aureus experimental abscesses. , 1986, The Journal of antimicrobial chemotherapy.

[5]  S. Eykyn,et al.  TREATMENT OF MULTIRESISTANT SALMONELLA TYPHI WITH ORAL CIPROFLOXACIN , 1987, The Lancet.

[6]  H. Zeiler Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin. , 1985, Drugs under experimental and clinical research.

[7]  D. Gibson,et al.  Studies on ciprofloxacin therapy of experimental Legionnaires' disease. , 1985, The Journal of infection.

[8]  R. Eng,et al.  The effect of ciprofloxacin on methicillin-resistant Staphylococcus aureus. , 1986, The Journal of antimicrobial chemotherapy.

[9]  J. Kurz,et al.  Isolation and structural elucidation of urinary metabolites of ciprofloxacin. , 1986, Arzneimittel-Forschung.

[10]  D. Raoult,et al.  Ciprofloxacin therapy for Mediterranean spotted fever , 1986, Antimicrobial Agents and Chemotherapy.

[11]  H. Neu,et al.  ORAL CIPROFLOXACIN THERAPY OF INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA , 1986, The Lancet.

[12]  G. Drusano,et al.  Dose ranging study and constant infusion evaluation of ciprofloxacin , 1986, Antimicrobial Agents and Chemotherapy.

[13]  A. Espinel-Ingroff,et al.  Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses , 1986, Antimicrobial Agents and Chemotherapy.

[14]  C. Gaudreau,et al.  Comparative in vitro activity of four quinolones and four other agents against enteropathogens , 1987 .

[15]  H. Tanimura,et al.  Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans. , 1986, Arzneimittel-Forschung.

[16]  W. Roszkowski,et al.  The Effect of Subinhibitory Concentrations of selected Antibiotics on Bacteria-Phagocyte Interaction , 1985 .

[17]  J. Reinhardt,et al.  Comparative in vitro activities of selected antimicrobial agents against Aeromonas species and Plesiomonas shigelloides , 1985, Antimicrobial Agents and Chemotherapy.

[18]  L. Peterson,et al.  Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. , 1986, The Journal of antimicrobial chemotherapy.

[19]  H. Ingham,et al.  TREATMENT OF SALMONELLA TYPHI CARRIER STATE WITH CIPROFLOXACIN , 1985, The Lancet.

[20]  B. Azadian,et al.  Two Neutropenic Patients with Multiple Resistant Pseudomonas Aeruginosa Septicaemia Treated with Ciprofloxacin , 1987, Journal of the Royal Society of Medicine.

[21]  C. Ramírez-Ronda,et al.  Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. , 1987, The American journal of medicine.

[22]  H. Neu,et al.  Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species. , 1987, Chemotherapy.

[23]  R. N. Brogden,et al.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. , 1985, Drugs.

[24]  R. Goering,et al.  Overview of preclinical studies with ciprofloxacin. , 1987, The American journal of medicine.

[25]  F. Soriano,et al.  Activity of nine antimicrobial agents against Corynebacterium group D2 strains isolated from clinical specimens and skin , 1987, Antimicrobial Agents and Chemotherapy.

[26]  C. Bersani,et al.  Effect of beta-lactam antibiotics on migration and bactericidal activity of human phagocytes , 1983, Antimicrobial Agents and Chemotherapy.

[27]  I. Shalit,et al.  Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. , 1987, The American journal of medicine.

[28]  G. Drusano,et al.  Multiple‐dose ciprofloxacin dose ranging and kinetics , 1985, Clinical pharmacology and therapeutics.

[29]  G. Drusano,et al.  Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers , 1987, Antimicrobial Agents and Chemotherapy.

[30]  B. Azadian,et al.  Emergence of ciprofloxacin-resistant Pseudomonas aeruginosa after combined therapy with ciprofloxacin and amikacin. , 1986, The Journal of antimicrobial chemotherapy.

[31]  T. Moreland,et al.  Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. , 1987, The Journal of antimicrobial chemotherapy.

[32]  D. Dennig,et al.  Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin. , 1987, Onkologie.

[33]  A. Dalhoff,et al.  Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration. , 1986, Chemotherapy.

[34]  A. Staib,et al.  Gyrase-inhibitors impair caffeine elimination in man. , 1987, Methods and findings in experimental and clinical pharmacology.

[35]  R. Auckenthaler,et al.  In-vitro activity of newer quinolones against aerobic bacteria. , 1986, The Journal of antimicrobial chemotherapy.

[36]  A. Lesse,et al.  Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. , 1987, The American journal of medicine.

[37]  R. Greenblatt,et al.  Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. , 1987, The American journal of medicine.

[38]  R. Maserati,et al.  Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis , 1985, Antimicrobial Agents and Chemotherapy.

[39]  J. Righter Ciprofloxacin treatment of Staphylococcus aureus infections. , 1987, The Journal of antimicrobial chemotherapy.

[40]  M. McElrath,et al.  The Pharmacokinetics and Serum and Urine Bactericidal Activity of Ciprofloxacin , 1985, Journal of clinical pharmacology.

[41]  Y. Michel-Briand,et al.  Elimination of plasmids from Enterobacteriaceae by 4-quinolone derivatives. , 1986, The Journal of antimicrobial chemotherapy.

[42]  I. Casin,et al.  In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi , 1986, Antimicrobial Agents and Chemotherapy.

[43]  H. Neu Ciprofloxacin: an overview and prospective appraisal. , 1987, The American journal of medicine.

[44]  M. Bergeron,et al.  Tissue penetration of ciprofloxacin after single and multiple doses , 1986, Antimicrobial Agents and Chemotherapy.

[45]  R. Fass Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections , 1987, Antimicrobial Agents and Chemotherapy.

[46]  T. Bergan,et al.  Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora , 1986, Antimicrobial Agents and Chemotherapy.

[47]  A. Forsgren,et al.  4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[48]  J. Timm,et al.  Low dose ciprofloxacin in respiratory tract infections a randomized comparison with doxycycline in general practice , 1987 .

[49]  R. Auckenthaler,et al.  Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis , 1987, Antimicrobial Agents and Chemotherapy.

[50]  J. Rahal,et al.  Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci , 1986, Antimicrobial Agents and Chemotherapy.

[51]  G. Bodey,et al.  In vitro susceptibility of Acinetobacter species to various antimicrobial agents , 1986, Antimicrobial Agents and Chemotherapy.

[52]  A. Wronski,et al.  Ciprofloxacin in acute male gonorrhea. , 1986, Arzneimittel-Forschung.

[53]  D. Reeves,et al.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound. , 1984, The Journal of antimicrobial chemotherapy.

[54]  D. Badenoch,et al.  Oral ciprofloxacin as prophylaxis for optical urethrotomy. , 1987, British journal of urology.

[55]  W. Wilson,et al.  Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. , 1987, The American journal of medicine.

[56]  M. Hodson,et al.  CIPROFLOXACIN-RESISTANT PSEUDOMONAS , 1985, The Lancet.

[57]  A. Forsgren,et al.  Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth , 1987, Antimicrobial Agents and Chemotherapy.

[58]  R. Wall,et al.  The comparative in-vitro activity of twelve 4-quinolone antimicrobials against Haemophilus ducreyi. , 1985, The Journal of antimicrobial chemotherapy.

[59]  D. Folta,et al.  Comparative activity of ciprofloxacin and other new agents against 1454 clinical isolates at a community hospital , 1985 .

[60]  H. Neu,et al.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria , 1984, Antimicrobial Agents and Chemotherapy.

[61]  M. Flepp,et al.  Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women , 1987, Antimicrobial Agents and Chemotherapy.

[62]  P. Ruane,et al.  Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. , 1987, The American journal of medicine.

[63]  M. Bergeron,et al.  Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients , 1986, Antimicrobial Agents and Chemotherapy.

[64]  R. Fass In vitro activity of ciprofloxacin (Bay o 9867) , 1983, Antimicrobial Agents and Chemotherapy.

[65]  B. Watt,et al.  Is ciprofloxacin active against clinically important anaerobes? , 1986, The Journal of antimicrobial chemotherapy.

[66]  G. Drusano An overview of the pharmacology of intravenously administered ciprofloxacin. , 1987, The American journal of medicine.

[67]  A. Bayer,et al.  Pharmacokinetics of ciprofloxacin in the elderly. , 1987, Respiration; international review of thoracic diseases.

[68]  R. Lowry,et al.  Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. , 1986, The Journal of antimicrobial chemotherapy.

[69]  M. Leyland,et al.  Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. , 1986, The Journal of antimicrobial chemotherapy.

[70]  J. Crane,et al.  Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. , 1986, The Journal of antimicrobial chemotherapy.

[71]  S. Suerbaum,et al.  Influence of beta-lactam antibiotics and ciprofloxacin on cell envelope of Escherichia coli , 1987, Antimicrobial Agents and Chemotherapy.

[72]  I. Shalit,et al.  In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid , 1985, Antimicrobial Agents and Chemotherapy.

[73]  E. Perea,et al.  Activities of new quinoline derivatives against genital pathogens , 1985, Antimicrobial Agents and Chemotherapy.

[74]  E. Perea,et al.  Comparative clinical efficacy of two different single-dose ciprofloxacin treatments for uncomplicated gonorrhea. , 1986, Sexually transmitted diseases.

[75]  R. Eng,et al.  Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus , 1985, Antimicrobial Agents and Chemotherapy.

[76]  A. Forsgren,et al.  Effect of tetracycline on the phagocytic function of human leukocytes. , 1974, The Journal of infectious diseases.

[77]  H. Young,et al.  Ciprofloxacin versus ampicillin and probenecid in the treatment of uncomplicated gonorrhoea in men. , 1987, The Journal of antimicrobial chemotherapy.

[78]  R. Goering,et al.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes , 1984, Antimicrobial Agents and Chemotherapy.

[79]  A. Digranes In vitro activity of amifloxacin (WIN 49,375) compared with those of ciprofloxacin and ofloxacin. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology.

[80]  S. Pattyn,et al.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives , 1984, Antimicrobial Agents and Chemotherapy.

[81]  C. R. Smith,et al.  The adverse effects of fluoroquinolones. , 1987, The Journal of antimicrobial chemotherapy.

[82]  G. Drusano,et al.  Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers , 1985, Antimicrobial Agents and Chemotherapy.

[83]  I. Fong,et al.  Ciprofloxacin concentrations in bone and muscle after oral dosing , 1986, Antimicrobial Agents and Chemotherapy.

[84]  P. Ball,et al.  Ciprofloxacin: an overview of adverse experiences. , 1986, The Journal of antimicrobial chemotherapy.

[85]  J. Ariza,et al.  In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. , 1986, The Journal of antimicrobial chemotherapy.

[86]  K. Yamaguchi,et al.  The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. , 1986, The Journal of antimicrobial chemotherapy.

[87]  B. O’Brien,et al.  Ciprofloxacin: an update on clinical experience. , 1987, The American journal of medicine.

[88]  小林 宏行他 Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections. , 1986 .

[89]  J. Hamilton-miller,et al.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers , 1984, Antimicrobial Agents and Chemotherapy.

[90]  L. Sollenberger,et al.  Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome. , 1986, The Journal of antimicrobial chemotherapy.

[91]  H. Lode,et al.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration , 1985, Antimicrobial Agents and Chemotherapy.

[92]  D. Honeybourne,et al.  CIPROFLOXACIN PENETRATION INTO LUNGS , 1987, The Lancet.

[93]  J. Bosso,et al.  Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. , 1987, The American journal of medicine.

[94]  C. Hart,et al.  Evaluation of ciprofloxacin 500 mg twice daily for one week in treating uncomplicated gonococcal chlamydial, and non-specific urethritis in men. , 1986, Genitourinary medicine.

[95]  T. Bergan,et al.  Tolerance of ciprofloxacin at injection site, systemic safety and effect on electroencephalogram. , 1987, Chemotherapy.

[96]  J. Klastersky,et al.  Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin , 1986, Antimicrobial Agents and Chemotherapy.

[97]  C. Licitra,et al.  Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection , 1987, Antimicrobial Agents and Chemotherapy.

[98]  F. R. Venezio,et al.  Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria , 1986, Antimicrobial Agents and Chemotherapy.

[99]  H. Shwachman,et al.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. , 1958, A.M.A. journal of diseases of children.

[100]  A. Bayer,et al.  Comparative efficacy of ciprofloxacin and ceftriaxone in experimental arthritis caused by Escherichia coli , 1986, Antimicrobial Agents and Chemotherapy.

[101]  S. Esposito,et al.  In vitro synergy of ciprofloxacin and three other antibiotics against Bacteroides fragilis. , 1987, Drugs under experimental and clinical research.

[102]  G. Ridgway,et al.  The Activity of Ciprofloxacin and Other 4-Quinolones Against Chlamydia trachomatis and Mycoplasmas In Vitro , 1986 .

[103]  H. Neu,et al.  Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. , 1987, The American journal of medicine.

[104]  A. Mazzone,et al.  Ciprofloxacin concentrations in human fluids and tissues following a single oral dose. , 1987, International journal of clinical pharmacology research.

[105]  D. Hooper,et al.  Mechanisms of action of and resistance to ciprofloxacin. , 1987, The American journal of medicine.

[106]  L. Eron,et al.  Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria , 1985, Antimicrobial Agents and Chemotherapy.

[107]  K. Schmidt,et al.  Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization. , 1987, Journal of chromatography.

[108]  M. Rosseneu,et al.  The pharmacokinetics of ciprofloxacin in patients with impaired renal function. , 1985, The Journal of antimicrobial chemotherapy.

[109]  I. Fong,et al.  Treatment of nongonococcal urethritis with ciprofloxacin. , 1987, The American journal of medicine.

[110]  R. Rubin,et al.  New approaches to the treatment of urinary tract infection. , 1987, The American journal of medicine.

[111]  M. Sande,et al.  Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus , 1986, Antimicrobial Agents and Chemotherapy.

[112]  D. Ilstrup,et al.  Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. , 1986, The Journal of antimicrobial chemotherapy.

[113]  N. Høiby,et al.  FREQUENT ANTIBIOTIC THERAPY IMPROVES SURVIVAL OF CYSTIC FIBROSIS PATIENTS WITH CHRONIC PSEUDOMONAS AERUGINOSA INFECTION , 1983 .

[114]  C. Sanders,et al.  Efficacy of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis. , 1987, The Journal of infectious diseases.

[115]  G. Krol,et al.  Liquid Chromatographic Analysis of Ciprofloxacin and Ciprofloxacin Metabolites in Body Fluids , 1986 .

[116]  Jerome J. Schentag,et al.  Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. , 1987, The American journal of medicine.

[117]  C Thornsberry,et al.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae , 1985, Antimicrobial Agents and Chemotherapy.

[118]  M. Cynamon,et al.  Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare , 1986, Antimicrobial Agents and Chemotherapy.

[119]  C. Mcnulty,et al.  Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents , 1985, Antimicrobial Agents and Chemotherapy.

[120]  R. Stern,et al.  Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. , 1987, The American journal of medicine.

[121]  H. Humphreys,et al.  CIPROFLOXACIN-RESISTANT STAPHYLOCOCCUS AUREUS , 1985, The Lancet.

[122]  R. Greenwood,et al.  Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis , 1986, Antimicrobial Agents and Chemotherapy.

[123]  R. Echols,et al.  Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin , 1987, Antimicrobial Agents and Chemotherapy.

[124]  L. Preheim,et al.  CIPROFLOXACIN AND ANTACIDS , 1986, The Lancet.

[125]  M. Rozenberg-Arska,et al.  Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. , 1985, The Journal of infectious diseases.

[126]  M. Stieglitz,et al.  Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants. , 1985, Chemotherapy.

[127]  G. Eliopoulos,et al.  InVitro Activity OfCiprofloxacin, aNewCarboxyquinoline Antimicrobial Agent , 1984 .

[128]  S. Gollapudi,et al.  Effect of ciprofloxacin on mitogen-stimulated lymphocyte proliferation , 1986, Antimicrobial Agents and Chemotherapy.

[129]  M. Leyland,et al.  Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.

[130]  C. Norden,et al.  In vitro activity of ciprofloxacin against aerobic gram-negative bacteria , 1984, Antimicrobial Agents and Chemotherapy.

[131]  S. Raoof,et al.  Ciprofloxacin increases serum levels of theophylline. , 1987, The American journal of medicine.

[132]  H. Pichler,et al.  Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. , 1987, The American journal of medicine.

[133]  E. Hvidberg,et al.  Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. , 1987, The Journal of antimicrobial chemotherapy.

[134]  J. Selkon,et al.  CLINICAL RESISTANCE TO LONG-TERM ORAL CIPROFLOXACIN , 1985, The Lancet.

[135]  I. Nilsson-ehle Assay of ciprofloxacin and norfloxacin in serum and urine by high-performance liquid chromatography. , 1987, Journal of chromatography.

[136]  J. Klastersky,et al.  Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis. , 1985, The Journal of antimicrobial chemotherapy.

[137]  M. Delmée,et al.  Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile , 1986, Antimicrobial Agents and Chemotherapy.

[138]  M. Bergeron,et al.  Pharmacokinetics of Ciprofloxacin in Elderly Subjects , 1986, Pharmacotherapy.

[139]  J. Cohen,et al.  ANTIBIOTIC-INDUCED ENDOTOXIN RELEASE , 1985, The Lancet.

[140]  D. Gilbert,et al.  Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. , 1987, The American journal of medicine.

[141]  G. Drusano,et al.  Effect of dose size on bioavailability of ciprofloxacin , 1987, Antimicrobial Agents and Chemotherapy.

[142]  R. Fass Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. , 1987, The American journal of medicine.

[143]  R. Fass Treatment of skin and soft tissue infections with oral ciprofloxacin. , 1986, The Journal of antimicrobial chemotherapy.

[144]  H. Muytjens,et al.  Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. , 1985, The Journal of antimicrobial chemotherapy.

[145]  L. Ayers,et al.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid , 1984, Antimicrobial Agents and Chemotherapy.

[146]  U. Petersen,et al.  Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. , 1987, Arzneimittel-Forschung.

[147]  J. Crane,et al.  Uptake of ciprofloxacin by human neutrophils. , 1985, The Journal of antimicrobial chemotherapy.

[148]  M. Bergeron,et al.  Determination of ciprofloxacin in biological samples by reversed-phase high performance liquid chromatography. , 1986, Therapeutic drug monitoring.

[149]  G. Drusano,et al.  Absolute oral bioavailability of ciprofloxacin , 1986, Antimicrobial Agents and Chemotherapy.

[150]  S. T. Pottratz,et al.  Multiple‐dose ciprofloxacin kinetics in normal subjects , 1984, Clinical pharmacology and therapeutics.

[151]  B. Joos,et al.  Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin , 1985, Antimicrobial Agents and Chemotherapy.

[152]  C. Collins,et al.  In-vitro susceptibility of mycobacteria to ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.

[153]  A. Sivonen,et al.  Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland , 1987, Antimicrobial Agents and Chemotherapy.

[154]  R. Petrak,et al.  Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species , 1985, Antimicrobial Agents and Chemotherapy.

[155]  L. Bush,et al.  Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. , 1987, The American journal of medicine.

[156]  C. Bijleveld,et al.  CIPROFLOXACIN FOR CHOLANGITIS AFTER HEPATIC PORTOENTEROSTOMY , 1987, The Lancet.

[157]  M. Wood,et al.  Ciprofloxacin for soft tissue infections. , 1986, The Journal of antimicrobial chemotherapy.

[158]  H. Van Poppel,et al.  Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin. , 1986, Chemotherapy.

[159]  J. Domagala,et al.  New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. , 1986, Journal of medicinal chemistry.

[160]  R. J. Butland,et al.  ORAL CIPROFLOXACIN COMPARED WITH CONVENTIONAL INTRAVENOUS TREATMENT FOR PSEUDOMONAS AERUGINOSA INFECTION IN ADULTS WITH CYSTIC FIBROSIS , 1987, The Lancet.

[161]  R. Prabhala,et al.  In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867) , 1984, Antimicrobial Agents and Chemotherapy.

[162]  J. Smith The mode of action of 4-quinolones and possible mechanisms of resistance. , 1986, The Journal of antimicrobial chemotherapy.

[163]  F. Debruyne,et al.  Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. , 1985, Chemotherapy.

[164]  D. Badenoch,et al.  Oral ciprofloxacin as prophylaxis in transurethral resection of the prostate. , 1987, British journal of urology.

[165]  M. Leyland,et al.  CIPROFLOXACIN-RESISTANT STAPHYLOCOCCI , 1985, The Lancet.

[166]  N. Legakis,et al.  In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs. , 1985, The Journal of antimicrobial chemotherapy.

[167]  K. Fuursted Post-antibiotic effect and killing activity of ciprofloxacin against Staphylococcus aureus. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology.

[168]  J. Cohen,et al.  In-vitro study of the activity of ciprofloxacin alone and in combination against strains of Pseudomonas aeruginosa with multiple antibiotic resistance. , 1986, The Journal of antimicrobial chemotherapy.

[169]  A. Dalhoff,et al.  Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. , 1987, The American journal of medicine.

[170]  H. Stutman Summary of a workshop on ciprofloxacin use in patients with cystic fibrosis , 1987 .

[171]  E. Rodriguez-Noriega,et al.  Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections. , 1987, American Journal of Medicine.

[172]  M. Dudley,et al.  Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin , 1986, Antimicrobial Agents and Chemotherapy.

[173]  V. Sutter,et al.  Comparative activity of ciprofloxacin against anaerobic bacteria , 1985, Antimicrobial Agents and Chemotherapy.

[174]  C. Easmon,et al.  Ciprofloxacin treatment of systemic salmonella infection in sensitive and resistance mice. , 1985, The Journal of antimicrobial chemotherapy.

[175]  R. Spencer,et al.  Comparative in-vitro activity of five fluoroquinolones against mycobacteria. , 1987, The Journal of antimicrobial chemotherapy.

[176]  A. P. Ball,et al.  Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. , 1986, The Journal of antimicrobial chemotherapy.

[177]  G. Pankey,et al.  Ciprofloxacin in the treatment of bacterial skin infections , 1987 .

[178]  I. Phillips,et al.  Ciprofloxacin for treating urethral gonorrhoea in men. , 1986, Genitourinary medicine.

[179]  L. Peterson,et al.  Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. , 1987, The American journal of medicine.

[180]  T. Mulvihill,et al.  The in-vitro activity of some antimicrobial agents against methicillin-resistant Staphylococcus aureus. , 1985, The Journal of antimicrobial chemotherapy.

[181]  A. Newland,et al.  Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients. , 1986, The Journal of antimicrobial chemotherapy.

[182]  H. Muytjens,et al.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid , 1983, Antimicrobial Agents and Chemotherapy.

[183]  T. Bergan,et al.  Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. , 1987, The American journal of medicine.

[184]  H. Neu,et al.  The post-antimicrobial suppressive effect of quinolone agents. , 1987, Drugs under experimental and clinical research.

[185]  A. Forsgren Comparative in vitro Activity of Three New Quinolone Antibiotics against Recent Clinical Isolates , 1985 .

[186]  G. Cornaglia,et al.  In vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern European hospital , 1987, Antimicrobial Agents and Chemotherapy.

[187]  R. Greenwood,et al.  Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. , 1987, The American journal of medicine.

[188]  T. Golper,et al.  Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis , 1987, Antimicrobial Agents and Chemotherapy.

[189]  C. Perronne,et al.  Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination , 1987, Antimicrobial Agents and Chemotherapy.

[190]  H. Lode,et al.  Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections , 1987, Antimicrobial Agents and Chemotherapy.

[191]  A. Smith,et al.  Pharmacokinetics of ciprofloxacin in cystic fibrosis , 1987, Antimicrobial Agents and Chemotherapy.

[192]  C. Stratton,et al.  Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies , 1987, Antimicrobial Agents and Chemotherapy.

[193]  G. Ridgway,et al.  Comparative in vitro studies with 4-quinolone antimicrobials. , 1985, Drugs under experimental and clinical research.

[194]  H. Handsfield,et al.  Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men , 1986, Antimicrobial Agents and Chemotherapy.

[195]  B. Angelucci,et al.  Oral ciprofloxacin in the treatment of uncomplicated gonococcal urethritis in men. , 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[196]  B. Régnier,et al.  Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis , 1987, Antimicrobial Agents and Chemotherapy.

[197]  D. Waaij,et al.  Colonization resistance of the digestive tract: clinical consequences and implications , 1982 .

[198]  G. Ridgway,et al.  Single dose ciprofloxacin for treating gonococcal infections in men. , 1985, Genitourinary medicine.

[199]  C. Norden,et al.  Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. , 1985, The Journal of infectious diseases.

[200]  M. Zweerink,et al.  Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids , 1986, Antimicrobial Agents and Chemotherapy.

[201]  U. Ullmann,et al.  Influence of various antimicrobial agents on the chemiluminescence of phagocytosing human granulocytes. , 1986, Chemotherapy.

[202]  V. Labombardi,et al.  Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. , 1987, The American journal of medicine.

[203]  A. Digranes,et al.  In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim. , 1985, Chemotherapy.

[204]  D. Reeves,et al.  RESISTANCE TO CIPROFLOXACIN , 1985, The Lancet.

[205]  J. Pennington,et al.  Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia , 1984, Antimicrobial Agents and Chemotherapy.

[206]  H. Giamarellou,et al.  Use of intravenous ciprofloxacin in difficult-to-treat infections. , 1987, The American journal of medicine.

[207]  P. Piot,et al.  Antimicrobial susceptibility and characterization of outer membrane proteins of Haemophilus ducreyi isolated in Thailand , 1985, Journal of clinical microbiology.

[208]  H. Dupont,et al.  Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. , 1987, Annals of internal medicine.

[209]  A. Bayer,et al.  Efficacy of ciprofloxacin in experimental arthritis caused by Escherichia coli--in vitro-in vivo correlations. , 1985, The Journal of infectious diseases.

[210]  G. Lindsay,et al.  Penetration of ciprofloxacin into aqueous humor. , 1986, Transactions of the ophthalmological societies of the United Kingdom.

[211]  L. Parish,et al.  Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime. , 1987, The American journal of medicine.